Phase 1/2a study of BAL101553, a novel tumor checkpoint controller, administered as 48-h infusion in patients with advanced solid tumorsMarkus Joerger,Michael Mark,Anastasios Stathis,Dagmar Hess,Silvia Stuedeli,Simona Berardi,Thomas Kaindl, Patrice Larger,Roger Von Moos,Cristiana SessaSWISS MEDICAL WEEKLY(2018)引用 0|浏览1暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要